Active, not recruitingPHASE1, PHASE2NCT05975021

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

Studying Cardiogenic shock

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Windtree Therapeutics
Principal Investigator
Steven G Simonson, MD
Windtree Therapeutics, Inc.
Intervention
Istaroxime(drug)
Enrollment
20 enrolled
Eligibility
18-85 years · All sexes
Timeline
20242026

Study locations (15)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05975021 on ClinicalTrials.gov

Other trials for Cardiogenic shock

Additional recruiting or active studies for the same condition.

See all trials for Cardiogenic shock

← Back to all trials